VRAYLAR®

Hold Company

ABBVIE

Learn More

Dosage and Administration

CAPSULE;ORAL

Specification

EQ 1.5MG BASE; EQ 3MG BASE; EQ 4.5MG BASE; EQ 6MG BASE

Indication

VRAYLAR® is mainly used for adult schizophrenia, bipolar I bipolar disorder and major depressive disorder.

Use

Instructions for Use

API

CARIPRAZINE HYDROCHLORIDE

API Structure

We Supply

CARIPRAZINE HYDROCHLORIDE

Note:

In-house Standard
Facility GMP
Product GMP
DMF in processing

null

Note:

null

null

Note:

null

Drug Patent

Patent No	Expiration Date
7737142	2029/9/17
7943621	2028/12/16
RE47350	2029/7/16
RE49110	2029/7/16
RE49302	2029/7/16

API Patent

Patent No	Expiration Date
7737142	2029/9/17
7943621	2028/12/16

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.